Elgemtumab

N/A

Report date: 2024/01/02 20:03:52

Base Information

Drug NameElgemtumab
Drug Alias NameNOV-6LJM-716
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionReceptor tyrosine-protein kinase erbB-3 antagonists
TargetsReceptor tyrosine-protein kinase erbB-3
Therapy Area/IndicationsHead and Neck NeoplasmsStomach NeoplasmsBreast Neoplasms +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[13] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesMorphosys AgNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesNovartis Pharma Ag
Inactive CompaniesN/A
Active IndicationsBreast Neoplasms
Inactive IndicationsHead and Neck NeoplasmsStomach NeoplasmsSquamous Cell Carcinoma of Head and Neck +[5] 

Other Information

ATC CodeN/A
Related LinksN/A